LONDON (The Deal) -- The U.K.'s Reckitt Benckiser said Wednesday it was leaning toward a separate listing for its prescription pharmaceuticals unit, whose core Suboxone heroin-withdrawal aid is losing U.S. market share to generic competition.
The Slough, England company, which is reportedly a leading contender in the $10 billion-plus auction for Merck & Co.'s consumer healthcare unit, announced a review of the pharma division in October.
"All options are on the table but we believe a capital markets solution is emerging as a strong option," CEO Rakesh Kapoor told analysts on a conference call accompanying a first-quarter trading bulletin.
Kapoor also hinted at disposals elsewhere in the company, but declined to specify selloff candidates.
"In the past RB has basically been talked about in the area of M&A," he said. "I think M&A should include B and the B part is to really take a look at our portfolio and think about which pieces of our portfolio perhaps need a solution that is different from being in the company."
The "capital markets solution" for the pharma business would entail a public listing, CFO Adrian Hennah clarified. A spokeswoman said both an IPO or a spinoff were under consideration.
The company began the pharma review after the Food and Drug Administration approved two generic alternatives to Suboxone. Reckitt then discontinued its Suboxone tablets and switched to a cheaper, sublingual version of the drug. That film version had a 64% market share in the U.S. in the first quarter, Reckitt said.
"We continue to be of the view that we will lose some further market share of film in the U.S. How much we will lose is a question of the battle between clinical preference for our product...but, on the other hand, there is an economic dimension to the decision making," said Hennah.